Expert retina and uveitis specialists will help support the growth and innovation of ANI’s ophthalmology and retina franchise ...

The 5th Eye Care Summit for the Middle East, Africa, and Russia (MEAR) region, under the patronage of AbbVie, the global ...

Shares of Regeneron Pharmaceuticals REGN have gained 21.5% year to date compared with the industry’s growth of 10.2%. The ...

On the innovative side, there are ongoing trials for combining therapies—anti-VEGF plus steroids or laser—to get better and faster outcomes. AI-assisted retina exams are enabling doctors to detect DME ...

Chugai Pharma announces results from phase I/II study in Japan to evaluate the efficacy and safety of Port Delivery System with Ranibizumab in patients with nAMD & DME ...

An oral HIV drug helped patients with center-involved diabetic macular edema achieve improvements in visual acuity, according ...

While shares of Regeneron Pharmaceuticals are climbing this month, investors shouldn't find the stock too pricey, as it's ...

The FDA approved Eylea HD for the treatment of macular edema following retinal vein occlusion, according to a press ...

The US Food and Drug Administration (FDA) has approved aflibercept injection 8 mg (EYLEA HD) from Regeneron Pharmaceuticals ...

Coave Therapeutics has announced its lead gene therapy program, CoTx-101, for the treatment of retinal vascular diseases, ...

The FDA has approved Eylea HD (aflibercept) 8 mg to treat patients with macular edema following retinal vein occlusion (RVO) with dosing of up to every 8 weeks after an initial monthly dosing period.

The FDA also approved an every 4 week dosing regimen across all approved indications for patients who may not maintain a response on extended dosing intervals following successful initial treatment.